Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Perrone

Showing results (101-110 of 184) with videos related to

Pageof 19
Sort By:
Oncology Reports|May 21, 2011
DNA-flow cytometry (ploidy and s-phase fraction) as prognostic factor in a retrospective series of 515 primary breast-cancerS Pepe, A Ruggiero, M Delaurentiis, et al.
Current Cancer Drug Targets|August 12, 2008
FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancerD L Cortinovis, F Andriani, A Livio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1996
c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastasesC Carlomagno, F Perrone, C Gallo, et al.
International Journal of Oncology|July 13, 1999
The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancerS De Placido, R Lauria, C Carlomagno, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2000
Phase I study with weekly cisplatin-paclitaxel and concurrent radiotherapy in patients with carcinoma of the cervix uteriS Pignata, P Frezza, S Tramontana, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2001
Prognostic value of serum biological markers in patients with hepatocellular carcinomaR Parasole, F Izzo, F Perrone, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1996
Selecting high-risk early breast cancer patients: what to add to the number of metastatic nodes?F Perrone, C Carlomagno, R Lauria, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2004
Insurance for independent cancer trialsF Perrone, M Marangolo, F Di Costanzo, et al.
Oncology Reports|May 25, 2011
Prognostic-significance of multifocality in primary breast-cancerA Morabito, F Perrone, R Lauria, et al.
Lung Cancer (Amsterdam, Netherlands)|February 13, 2001
Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trialC Gridelli, S Cigolari, C Gallo, et al.
Pageof 19

Showing results (101-110 of 184) with videos related to

Sort By:
Pageof 19
Oncology Reports|May 21, 2011
DNA-flow cytometry (ploidy and s-phase fraction) as prognostic factor in a retrospective series of 515 primary breast-cancerS Pepe, A Ruggiero, M Delaurentiis, et al.
Current Cancer Drug Targets|August 12, 2008
FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancerD L Cortinovis, F Andriani, A Livio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1996
c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastasesC Carlomagno, F Perrone, C Gallo, et al.
International Journal of Oncology|July 13, 1999
The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancerS De Placido, R Lauria, C Carlomagno, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2000
Phase I study with weekly cisplatin-paclitaxel and concurrent radiotherapy in patients with carcinoma of the cervix uteriS Pignata, P Frezza, S Tramontana, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2001
Prognostic value of serum biological markers in patients with hepatocellular carcinomaR Parasole, F Izzo, F Perrone, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1996
Selecting high-risk early breast cancer patients: what to add to the number of metastatic nodes?F Perrone, C Carlomagno, R Lauria, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2004
Insurance for independent cancer trialsF Perrone, M Marangolo, F Di Costanzo, et al.
Oncology Reports|May 25, 2011
Prognostic-significance of multifocality in primary breast-cancerA Morabito, F Perrone, R Lauria, et al.
Lung Cancer (Amsterdam, Netherlands)|February 13, 2001
Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trialC Gridelli, S Cigolari, C Gallo, et al.
Pageof 19